DDX19B: A Non-Code RNA Molecule Regulating Genes, DNA Replication and Cell Signaling

Target Name: DDX19B

NCBI ID: G11269

DDX19B

DDX19B: A Non-Code RNA Molecule Regulating Genes, DNA Replication and Cell Signaling

DDX19B (double-stranded DNA fragment) is a protein that is expressed in various cell types of the human body, including blood cells, epithelial cells, and neurons. It is a non-coding RNA molecule that plays a crucial role in regulating gene expression, DNA replication, and repair, and is also involved in cell adhesion and signaling pathways.

The discovery and characterization of DDX19B was made by a research group led by Dr. Zhiyong Zhao at the University of California, San Diego. The Zhao lab identifiedDDX19B as a potential drug target and candidate biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

DDX19B is expressed in almost all human tissues and cells, and its levels are regulated by various factors, including DNA replication, cellular stress, and cellular signaling pathways. It is a key regulator of the homeostasis of the cell, and its dysfunction has been implicated in various diseases.

One of the key functions of DDX19B is its role in DNA replication. During DNA replication, DDX19B helps ensure that the double helix is accurately replicated, and that the new DNA molecule is free of errors. This is important for the maintenance of genetic accuracy and for the development and progression of cancer.

DDX19B is also involved in cell signaling pathways. It has been shown to play a role in the regulation of cell adhesion, a process that is critical for the development and maintenance of tissues and organs. In addition, DDX19B is involved in the regulation of neurotransmitter signaling pathways, and its dysfunction has been implicated in various neurodegenerative diseases.

In addition to its role in cell signaling pathways, DDX19B is also a potential drug target. Its dysfunction has been implicated in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. By targeting DDX19B, researchers may be able to develop new treatments for these diseases.

The Zhao lab is currently working on developing small molecules that can specifically target DDX19B and modulate its function. These small molecules are being tested for their ability to inhibit the activity of DDX19B and to induce its degradation in cancer cells.

In conclusion, DDX19B is a non-coding RNA molecule that plays a crucial role in regulating gene expression, DNA replication, and repair, and is involved in cell adhesion and signaling pathways. Its dysfunction has been implicated in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The Zhao lab is currently working on developing small molecules that can specifically target DDX19B and modulate its function, with the goal of developing new treatments for these diseases.

Protein Name: DEAD-box Helicase 19B

Functions: ATP-dependent RNA helicase involved in mRNA export from the nucleus (PubMed:10428971). Rather than unwinding RNA duplexes, DDX19B functions as a remodeler of ribonucleoprotein particles, whereby proteins bound to nuclear mRNA are dissociated and replaced by cytoplasmic mRNA binding proteins (PubMed:10428971)

The "DDX19B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DDX19B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets